Voriconazole for Injection 200mg

• Customization: Available
• Dossier: Ctd,Actd
• GMP: Chinese GMP
• Model NO.: Powder Injection
• Packing: Accoring to Client Requiremen
• Payment: Tt
• Transport Package: Free
• Specification: 200mg
• Trademark: Sinolead
• Origin: China

Product Description

Basic Info.

 

Generic Name	Voriconazole for Injection 200mg
Strength	20mg/2ml
Packing	10vials/box
Origin	China

Component:
Voriconazole

Character:

This product is white or white powder.

Indications:

This product is a broad spectrum triazole antifungal drug, its indications are as follows:

Treatment of invasive aspergillosis.

For the treatment of severe invasive infections caused by fluconazol-resistant candida bacteria (including Candida claris).

Treat severe infections caused by Actinomyces pedis and Fusarium.

This product should be used primarily for the treatment of progressive, potentially life-threatening infections in immunodeficient patients.

 

Usage and dosage:

This product is dissolved with 5ml special solvent before intravenous infusion, and then diluted to 2 ~ 5mg/ml. This product should not be used for intravenous injection.

It is recommended that the maximum intravenous infusion speed of this product should not exceed 3mg/kg per hour, and the infusion time of each bottle after dilution should be more than 1 to 2 hours.

Adult medicine

Intravenous and oral interchangeably

Whether given intravenously or orally, the first load dose should be given on the first day of first administration so that the blood concentration is close to the steady-state concentration on the first day of administration. Due to the high bioavailability of oral tablets (96%), intravenous and oral delivery routes can be interchangeable when clinically indicated.

Matters needing attention:

Visual impairment: The effect of voriconazole on visual function beyond 28 days of treatment is unknown. If treatment continues for more than 28 days, visual function should be monitored, including visual acuity, visual range, and color vision.

Hepatotoxicity: In clinical trials, severe hepatic adverse events (including hepatitis, cholestasis, and fatal fulminant liver failure) were uncommon in the voriconazole treatment group. Hepatotoxic reactions have been reported mainly in patients with severe underlying diseases (mainly hematologic malignancies). Liver reactions, including hepatitis and jaundice, can occur in patients with no other established risk factors. Abnormal liver function usually improves when the drug is discontinued.

Monitoring liver function: Liver function should be checked before and during voriconazole treatment. Liver function should be routinely monitored at the beginning of treatment and during treatment to prevent more severe liver damage. Monitoring should include laboratory tests of liver function (especially liver function tests and bilirubin). If the clinical signs and symptoms are consistent with the development of liver disease, discontinuation should be considered.